Literature DB >> 30587290

Cefiderocol for treatment of complicated urinary tract infections.

Simon Portsmouth1, Roger Echols2, Tsutae Den Nagata3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30587290     DOI： 10.1016/S1473-3099(18)30721-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  3 in total

1.  Acinetobacter baumannii response to cefiderocol challenge in human urine.

Authors:  Brent Nishimura; Jenny Escalante; Marisel R Tuttobene; Tomás Subils; Vyanka Mezcord; Camila Pimentel; Nardin Georgeos; Fernando Pasteran; Cecilia Rodriguez; Rodrigo Sieira; Luis A Actis; Marcelo E Tolmasky; Robert A Bonomo; María Soledad Ramirez
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

2.  Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection.

Authors:  Diana A Mabayoje; Caoimhe NicFhogartaigh; Benny P Cherian; Mei Gie Meiqi Tan; David W Wareham
Journal:  JAC Antimicrob Resist       Date:  2021-06-15

3.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Shazad Mushtaq; Zahra Sadouki; Anna Vickers; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.